Mhairi Maskew

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9210441/publications.pdf

Version: 2024-02-01

117625 155660 3,768 106 34 55 citations h-index g-index papers 111 111 111 4436 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1002015.	8.4	232
2	Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLoS Medicine, 2012, 9, e1001304.	8.4	199
3	Treatment Outcomes of HIV-Infected Adolescents Attending Public-Sector HIV Clinics Across Gauteng and Mpumalanga, South Africa. AIDS Research and Human Retroviruses, 2013, 29, 892-900.	1.1	140
4	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 428-437.	2.1	119
5	Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide Laboratory Cohort. Clinical Infectious Diseases, 2018, 66, S111-S117.	5.8	114
6	Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Tropical Medicine and International Health, 2010, 15, 405-13.	2.3	100
7	Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. Aids, 2011, 25, 1761-1769.	2.2	98
8	Loss to followâ€up before and after delivery among women testing <scp>HIV</scp> positive during pregnancy in Johannesburg, South Africa. Tropical Medicine and International Health, 2013, 18, 451-460.	2.3	94
9	Trivalent Inactivated Influenza Vaccine in African Adults Infected With Human Immunodeficient Virus: Double Blind, Randomized Clinical Trial of Efficacy, Immunogenicity, and Safety. Clinical Infectious Diseases, 2011, 52, 128-137.	5.8	87
10	Patient Retention From HIV Diagnosis Through One Year on Antiretroviral Therapy at a Primary Health Care Clinic in Johannesburg, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e39-e46.	2.1	87
11	Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. Aids, 2011, 25, 1603-1609.	2.2	83
12	Gender Differences in Mortality and CD4 Count Response Among Virally Suppressed HIV-Positive Patients. Journal of Women's Health, 2013, 22, 113-120.	3.3	80
13	Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa. PLoS Medicine, 2018, 15, e1002589.	8.4	80
14	Cohort Profile: The Themba Lethu Clinical Cohort, Johannesburg, South Africa. International Journal of Epidemiology, 2013, 42, 430-439.	1.9	79
15	Mobility and Clinic Switching Among Postpartum Women Considered Lost to HIV Care in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 383-389.	2.1	79
16	High Rates of Survival, Immune Reconstitution, and Virologic Suppression on Second-Line Antiretroviral Therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 500-506.	2.1	73
17	Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. Aids, 2011, 25, 2027-2036.	2.2	71
18	Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. International Journal of Infectious Diseases, 2009, 13, 488-492.	3.3	70

#	Article	IF	Citations
19	The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. Journal of the International AIDS Society, 2010, 13, 49-49.	3.0	70
20	A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infectious Diseases, 2011, 11, 244.	2.9	58
21	Adolescent HIV treatment in South Africa's national HIV programme: a retrospective cohort study. Lancet HIV,the, 2019, 6, e760-e768.	4.7	55
22	Attrition through Multiple Stages of Pre-Treatment and ART HIV Care in South Africa. PLoS ONE, 2014, 9, e110252.	2.5	55
23	Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. PLoS ONE, 2018, 13, e0204020.	2.5	53
24	Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. Aids, 2013, 27, 645-650.	2.2	51
25	Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 547-554.	2.1	51
26	Kaposi's Sarcoma in HIVâ€infected patients in South Africa: Multicohort study in the antiretroviral therapy era. International Journal of Cancer, 2014, 135, 2644-2652.	5.1	48
27	The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. South African Medical Journal, 2008, 98, 541-4.	0.6	47
28	Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. Journal of the International AIDS Society, 2014, 17, 18651.	3.0	44
29	Anemia among HIV-Infected Patients Initiating Antiretroviral Therapy in South Africa: Improvement in Hemoglobin regardless of Degree of Immunosuppression and the Initiating ART Regimen. Journal of Tropical Medicine, 2013, 2013, 1-6.	1.7	40
30	Treatment outcomes after 7 years of public-sector HIV treatment. Aids, 2012, 26, 1823-1828.	2.2	38
31	Treatment Response and Mortality among Patients Starting Antiretroviral Therapy with and without Kaposi Sarcoma: A Cohort Study. PLoS ONE, 2013, 8, e64392.	2.5	38
32	Incidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa. Pediatric Infectious Disease Journal, 2016, 35, e164-e170.	2.0	38
33	Poorer ART Outcomes with Increasing Age at a Large Public Sector HIV Clinic in Johannesburg, South Africa. Journal of the International Association of Providers of AIDS Care, 2012, 11, 57-65.	1.2	37
34	Cervical cancer risk in women living with HIV across four continents: A multicohort study. International Journal of Cancer, 2020, 146, 601-609.	5.1	37
35	Tuberculosis Treatment and Risk of Stavudine Substitution in Firstâ€Line Antiretroviral Therapy. Clinical Infectious Diseases, 2009, 48, 1617-1623.	5.8	35
36	Effect of Pregnancy and the Postpartum Period on Adherence to Antiretroviral Therapy Among HIV-Infected Women Established on Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 477-480.	2.1	34

#	Article	IF	CITATIONS
37	Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in South Africa and Kenya. PLoS Medicine, 2019, 16, e1002912.	8.4	33
38	Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS ONE, 2016, 11, e0161469.	2.5	32
39	Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa. AIDS Patient Care and STDs, 2017, 31, 205-212.	2.5	32
40	The interplay between <scp>CD</scp> 4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resourceâ€imited setting. Tropical Medicine and International Health, 2013, 18, 619-631.	2.3	31
41	Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study. Lancet HIV,the, 2015, 2, e368-e375.	4.7	29
42	A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial. PLoS Medicine, 2020, 17, e1003226.	8.4	29
43	Impact of nutritional supplementation on immune response, body mass index and bioelectrical impedance in HIV-positive patients starting antiretroviral therapy. Nutrition Journal, 2013, 12, 111.	3.4	28
44	Initiating antiretroviral therapy for HIV at a patient's first clinic visit. Aids, 2017, 31, 1611-1619.	2.2	27
45	Prevalence of peripheral neuropathy in antiretroviral therapy naÃ⁻ve HIV-positive patients and the impact on treatment outcomes—a retrospective study from a large urban cohort in Johannesburg, South Africa. Journal of NeuroVirology, 2012, 18, 162-171.	2.1	26
46	Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study. BMJ Open, 2020, 10, e030228.	1.9	25
47	HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antiviral Therapy, 2010, 15, 499-503.	1.0	24
48	Clinical Predictors of Culture-confirmed Pulmonary Tuberculosis in Children in a High Tuberculosis and HIV Prevalence Area. Pediatric Infectious Disease Journal, 2015, 34, e206-e210.	2.0	24
49	Attrition in HIV care following HIV diagnosis: a comparison of the preâ€UTT and UTT eras in South Africa. Journal of the International AIDS Society, 2021, 24, e25652.	3.0	24
50	Insights into Adherence among a Cohort of Adolescents Aged 12–20 Years in South Africa: Reported Barriers to Antiretroviral Treatment. AIDS Research and Treatment, 2016, 2016, 1-12.	0.7	23
51	Cervical cancer risk and impact of Papâ€based screening in HIVâ€positive women on antiretroviral therapy in Johannesburg, South Africa. International Journal of Cancer, 2017, 141, 488-496.	5.1	23
52	Pregnancy and Virologic Response to Antiretroviral Therapy in South Africa. PLoS ONE, 2011, 6, e22778.	2.5	23
53	Prevalence of hepatitis B virus (HBV) co-infection in HBV serologically-negative South African HIV patients and retrospective evaluation of the clinical course of mono- and co-infection. International Journal of Infectious Diseases, 2012, 16, e268-e272.	3.3	21
54	Immune Recovery After Starting ART in HIV-Infected Patients Presenting and Not Presenting With Tuberculosis in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 142-145.	2.1	21

#	Article	lF	Citations
55	Incidence of Pregnancy after Initiation of Antiretroviral Therapy in South Africa: A Retrospective Clinical Cohort Analysis. Infectious Diseases in Obstetrics and Gynecology, 2012, 2012, 1-7.	1.5	20
56	Incidence and predictors of herpes zoster among antiretroviral therapy-na \tilde{A} -ve patients initiating HIV treatment in Johannesburg, South Africa. International Journal of Infectious Diseases, 2014, 23, 56-62.	3.3	20
57	Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa. Infectious Agents and Cancer, 2011, 6, 22.	2.6	19
58	Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. Journal of the International AIDS Society, 2012, 15, 13-13.	3.0	19
59	Acceptability and feasibility of a financial incentive intervention to improve retention in HIV care among pregnant women in Johannesburg, South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 453-460.	1.2	19
60	Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 113, 362-372.	0.4	18
61	Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. Journal of the International AIDS Society, 2020, 23, e25542.	3.0	18
62	Increases in regimen durability associated with the introduction of tenofovir at a large publicâ€sector clinic in Johannesburg, South Africa. Journal of the International AIDS Society, 2013, 16, 18794.	3.0	17
63	Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Services Research, 2017, 17, 41.	2.2	17
64	Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. BMJ Open, 2017, 7, bmjopen-2016-015620.	1.9	16
65	The right combination & Deprice and treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg, South Africa. Clinical Epidemiology, 2018, Volume 10, 17-29.	3.0	16
66	Kaposi's Sarcoma Associated-Herpes Virus (KSHV) Seroprevalence in Pregnant Women in South Africa. Infectious Agents and Cancer, 2010, 5, 14.	2.6	15
67	Simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE): protocol for a randomised evaluation. BMJ Open, 2017, 7, e016340.	1.9	15
68	The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. Journal of the International AIDS Society, 2014, 17, 19065.	3.0	14
69	Comparison of Pharmacy-Based Measures of Adherence to Antiretroviral Therapy as Predictors of Virological Failure. AIDS and Behavior, 2015, 19, 612-618.	2.7	14
70	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 30-38.	1.3	14
71	Developing a predictive risk model for firstâ€line antiretroviral therapy failure in South Africa. Journal of the International AIDS Society, 2016, 19, 20987.	3.0	14
72	Incident Pregnancy and Time to Death or AIDS among HIV-Positive Women Receiving Antiretroviral Therapy. PLoS ONE, 2013, 8, e58117.	2.5	14

#	Article	IF	CITATIONS
73	Prevalent Pregnancy, Biological Sex, and Virologic Response to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 489-494.	2.1	13
74	Zidovudine impairs immunological recovery on first-line antiretroviral therapy. Aids, 2013, 27, 2225-2232.	2.2	13
75	Kaposi Sarcoma-Associated Herpes Virus and Response to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 442-448.	2.1	12
76	CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIVâ€positive patients on antiretroviral therapy. Journal of the International AIDS Society, 2014, 17, 19139.	3.0	12
77	"My future is bright…I won't die with the cause of AIDS ― tenâ€year patient ART outcomes and experiences in South Africa. Journal of the International AIDS Society, 2018, 21, e25184.	3.0	12
78	Prevalence of TB symptoms, diagnosis and treatment among people living with HIV (PLHIV) not on ART presenting at outpatient clinics in South Africa and Kenya: baseline results from a clinical trial. BMJ Open, 2020, 10, e035794.	1.9	12
79	Variation in HIV care and treatment outcomes by facility in South Africa, 2011–2015: A cohort study. PLoS Medicine, 2021, 18, e1003479.	8.4	11
80	Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1040-1045.	1.2	10
81	Tenofovir stock shortages have limited impact on clinic―and patient―evel HIV treatment outcomes in public sector clinics in South Africa. Tropical Medicine and International Health, 2017, 22, 241-251.	2.3	10
82	Who is seeking antiretroviral treatment for <scp>HIV</scp> now? Characteristics of patients presenting in Kenya and South Africa in 2017â€2018. Journal of the International AIDS Society, 2019, 22, e25358.	3.0	10
83	The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Medicine, 2013, 14, 217-225.	2.2	9
84	Impact of choice of <scp>NRTI</scp> in firstâ€ine antiretroviral therapy: a cohort analysis of stavudine <i>vs</i> . tenofovir. Tropical Medicine and International Health, 2014, 19, 490-498.	2.3	9
85	Steep Declines in Pediatric AIDS Mortality in South Africa, Despite Poor Progress Toward Pediatric Diagnosis and Treatment Targets. Pediatric Infectious Disease Journal, 2020, 39, 843-848.	2.0	9
86	Human papillomavirus types in HIV seropositive men with penile warts in Johannesburg, South Africa. International Journal of STD and AIDS, 2011, 22, 107-109.	1.1	8
87	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 323-328.	2.1	8
88	Markers of poor adherence among adults with HIV attending Themba Lethu HIV Clinic, Helen Joseph Hospital, Johannesburg, South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 696-704.	1.8	8
89	The Impact of Choice of NNRTI on Short-Term Treatment Outcomes among HIV-Infected Patients Prescribed Tenofovir and Lamivudine in Johannesburg, South Africa. PLoS ONE, 2013, 8, e71719.	2.5	8
90	Prevalent tuberculosis and mortality among HAART initiators. Aids, 2012, 26, 770-773.	2.2	7

#	Article	IF	CITATIONS
91	Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes. HIV Medicine, 2017, 18, 595-603.	2.2	7
92	Retention in care and viral suppression after sameâ€day ART initiation: Oneâ€year outcomes of the SLATE I and II individually randomized clinical trials in South Africa. Journal of the International AIDS Society, 2021, 24, e25825.	3.0	7
93	Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open, 2017, 7, e013908.	1.9	6
94	Paediatric human immunodeficiency virus treatment outcomes from a resource-limited setting in South Africa: Highly active antiretroviral therapy alone is not enough. Vulnerable Children and Youth Studies, 2011, 6, 208-221.	1.1	5
95	CD4+ gain percentile curves for monitoring response to antiretroviral therapy in HIV-infected adults. Aids, 2015, 29, 1067-1075.	2.2	5
96	Impact of Viral Load Monitoring on Retention and Viral Suppression: A Regression Discontinuity Analysis of South Africa's National Laboratory Cohort. American Journal of Epidemiology, 2020, 189, 1492-1501.	3.4	5
97	The South African National HIV Pregnancy Cohort: evaluating continuity of care among women living with HIV. BMC Public Health, 2020, 20, 1662.	2.9	5
98	The Feasibility of Using Screening Criteria to Reduce Clinic Visits for Stable Patients on Antiretroviral Therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e82-e86.	2.1	4
99	HHVâ€8 seroprevalence in HIVâ€positive and HIVâ€negative populations. International Journal of Cancer, 2015, 136, 1243-1243.	5.1	4
100	Regimen durability in HIVâ€infected children and adolescents initiating firstâ€line antiretroviral therapy in a large public sector HIV cohort in South Africa. Tropical Medicine and International Health, 2018, 23, 650-660.	2.3	4
101	Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. PLoS ONE, 2018, 13, e0201955.	2.5	4
102	Tenofovir use and pregnancy among women initiating HAART. Aids, 2012, 26, 2393-2397.	2.2	3
103	Patient Perspectives of Quality of the Same-Day Antiretroviral Therapy Initiation Process in Gauteng Province, South Africa: Qualitative Dominant Mixed-Methods Analysis of the SLATE II Trial. Patient, 2021, 14, 175-186.	2.7	3
104	One Pill, Once a Day: Simplified Treatment Regimens and Retention in HIV Care. American Journal of Epidemiology, 2022, , .	3.4	2
105	Response to Lawn et al Aids, 2012, 26, 1728-1729.	2.2	0
106	NHL risk in HIV+ adults on antiretroviral therapy in four continents Journal of Clinical Oncology, 2016, 34, 1578-1578.	1.6	0